Bernd Schmidt
Chief Tech/Sci/R&D Officer presso SENSORION
Profilo
Bernd Schmidt is currently the Chief Technical Officer at Sensorion SA since 2023.
Prior to this, he worked as the Vice President-Product Delivery at Quell Therapeutics Ltd.
Mr. Schmidt is a graduate of Friedrich-Alexander University of Erlangen-Nuremberg.
Posizioni attive di Bernd Schmidt
| Società | Posizione | Inizio |
|---|---|---|
| SENSORION | Chief Tech/Sci/R&D Officer | 11/12/2023 |
Precedenti posizioni note di Bernd Schmidt
| Società | Posizione | Fine |
|---|---|---|
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formazione di Bernd Schmidt
| Friedrich-Alexander University of Erlangen-Nuremberg | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SENSORION | Health Technology |
| Aziende private | 1 |
|---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Bernd Schmidt
